455 related articles for article (PubMed ID: 34889359)
41. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
42. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
43. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract][Full Text] [Related]
44. Which novel agents hold the greatest promise in AML?
DiNardo CD
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101106. PubMed ID: 31779980
[TBL] [Abstract][Full Text] [Related]
45. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
Bohl SR; Bullinger L; Rücker FG
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
47. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Derman BA; Larson RA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
[TBL] [Abstract][Full Text] [Related]
48. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
49. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
50. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Arber DA; Erba HP
Am J Clin Pathol; 2020 Nov; 154(6):731-741. PubMed ID: 32864703
[TBL] [Abstract][Full Text] [Related]
52. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
Leuk Res; 2022 Nov; 122():106942. PubMed ID: 36108424
[TBL] [Abstract][Full Text] [Related]
54. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
55. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Talati C; Lancet JE
Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
[TBL] [Abstract][Full Text] [Related]
56. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
57. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
58. [New therapeutic agents for acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
[TBL] [Abstract][Full Text] [Related]
59. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
[TBL] [Abstract][Full Text] [Related]
60. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]